IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Premature Ovarian Failure (Genetic and Physiopathologic Analysis) (GéNIOP)
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Premature Ovarian Failure (POF), syndrome observed in young woman, present consequences on hormonal and leads at definitive infertility. It's a rare and complex syndrome and for this reason, we propose to initiate a collaborative team network to understand better his genetic and physiopathology.
We are going to realize a global study of this syndrome with clinical and fundamentals approaches. We wish that this project allows us to understand better the physiopathology of this rare disease. Finally, POF responsible genes identification is the base for future development of therapeutics approaches.
| Condition |
|---|
| Premature Ovarian Failure |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | Premature Ovarian Failure : Genetic and Physiopathologic Analysis |
| Estimated Enrollment: | 87 |
| Study Start Date: | March 2005 |
| Estimated Study Completion Date: | March 2009 |
| Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
|
|
2
Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
|
Detailed Description:
Premature ovarian failure (POF) is a rare but not exceptional disease concerning 0.1% of the more-than-thirty-years-old women. On the clinical aspect, patients present a primary or secondary amenorrhea depending on when the disease occurs in their lives. Infertility is most of the time definitive and the yet only available therapy is auto implantation of cryopreserved oocytes. Initiation of a substitutive hormonal treatment is also necessary to prevent the consequences of estrogenic hardship (i.e leading to osteoporosis).
POF has numerous possible origins, and can be linked to auto-immune diseases, metabolic disorders (i.e. galactosemia) or even genetic abnormalities. According to her origin, POF is characterized by (a) a depletion of primary follicles, (b) increased or accelerated follicle atresia (c) an alteration of the recruitment of dominant follicle and (d) stopped follicular maturation.
The purpose of our work is to organize a clinical and fundamental research network focussed on premature ovarian failure (POF). It will aim to collect clinical, biological, radiological and histological information on patients, and according to their phenotypes, to decide for searching possible genetic abnormalities leading to POF. And in the same time, the constitution of a broad tissue collection allows the study of ovarian transcripts, using POF as a pathologic model to describe ovaries and follicle development-involved genes.
Eligibility| Ages Eligible for Study: | 18 Years to 39 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion criteria :
Experimental group:
- 18 years <Age> 39 years
- Patient with amenorrhea since at least 3 months
- Patient with at least 1 FSH dosage > 30 mUI/L
- Patients between 40 and 45 years old with hormonal results indicating a POF declared before 39 years old will be included.
- Informed Consent Form Signature
Control group:
- 18 years <Age> 39 years
- Patient having a benign ovarian pathology justifying an ovarian surgery
- Informed Consent Form Signature
Exclusion criteria:
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00780897
| Contact: Philippe Touraine, MD, PhD | +33 1 42 16 02 11 | philippe.touraine@psl.aphp.fr |
| France | |
| Groupe Hopitalier Pitié-Salpêtrière | Recruiting |
| Paris, France, 75013 | |
| Contact: Philippe Touraine, MD, PhD +33 1 42 16 02 11 | |
| Principal Investigator: | Philippe Touraine, MD, PhD | Assistance Publique - Hôpitaux de Paris |
More Information
| Responsible Party: | Myriem Carrier, Department Clinical Research of Developpement |
| ClinicalTrials.gov Identifier: | NCT00780897 History of Changes |
| Other Study ID Numbers: |
P040801 |
| Study First Received: | October 27, 2008 |
| Last Updated: | October 27, 2008 |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
PREMATURE OVARIAN FAILURE (POF) GENETIC ANALYSIS PHYSIOPATHOLOGIC ANALYSIS |
Additional relevant MeSH terms:
|
Premature Birth Primary Ovarian Insufficiency Menopause, Premature Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications |
Ovarian Diseases Adnexal Diseases Genital Diseases, Female Gonadal Disorders Endocrine System Diseases |
ClinicalTrials.gov processed this record on August 16, 2017